Hosted on MSN14h
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus Therapeutics ARCT and partner CSL Seqirus, a renowned vaccine company, together reported encouraging results from a ...
biopharma-reporter20h
Self-amplifying mRNA COVID-19 vaccine shows superiority over conventional mRNA vaccine
A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity ...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus ...
GlobalData on MSN18d
Japan approves updated Covid-19 vaccine to tackle JN.1 variant
Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination ...
pharmaphorum10mon
CSL, Arcturus get first approval for self-assembling RNA jab
The Ministry of Health, Labour and Welfare (MHLW) gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also known as Lunar-COV19 – which will be commercialised in Japan by ...
24/7 Wall St2d
Arcturus Therapeutics Holdings Inc
The company's pipeline includes ARCT-810, a treatment for ornithine transcarbamylase deficiency in Phase 2 trials, ARCT-154, a COVID-19 vaccine candidate in Phase 3 trials in Vietnam, and ARCT-032 ...